CONMED (NYSE:CNMD) Updates FY 2025 Earnings Guidance

CONMED (NYSE:CNMD) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 4.480-4.530 for the period, compared to the consensus estimate of 4.500. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Analysts Set New Price Targets

CNMD has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of CONMED in a research report on Wednesday, October 8th. JPMorgan Chase & Co. reduced their price objective on CONMED from $58.00 to $52.00 and set a “neutral” rating for the company in a research note on Thursday, November 6th. Wells Fargo & Company reduced their target price on shares of CONMED from $57.00 to $47.00 and set an “equal weight” rating for the company in a research note on Thursday, November 6th. Piper Sandler dropped their price objective on CONMED from $68.00 to $55.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Finally, Bank of America reduced their price target on shares of CONMED from $65.00 to $52.00 and set a “neutral” rating for the company in a research report on Monday, December 8th. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $53.67.

CONMED Stock Up 1.3%

CNMD stock opened at $40.17 on Thursday. The firm has a market cap of $1.24 billion, a PE ratio of 19.60, a P/E/G ratio of 2.59 and a beta of 0.98. CONMED has a 12 month low of $38.32 and a 12 month high of $74.70. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.10 and a quick ratio of 0.95. The firm has a 50 day simple moving average of $43.25 and a 200 day simple moving average of $48.59.

CONMED (NYSE:CNMD) last announced its earnings results on Wednesday, November 5th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $1.05 by $0.03. CONMED had a return on equity of 14.22% and a net margin of 4.75%.The business had revenue of $337.93 million during the quarter, compared to the consensus estimate of $334.76 million. During the same period in the prior year, the business posted $1.05 earnings per share. CONMED’s revenue was up 6.7% compared to the same quarter last year. CONMED has set its FY 2025 guidance at 4.480-4.530 EPS. Equities research analysts forecast that CONMED will post 4.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CONMED

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Kelleher Financial Advisors acquired a new position in shares of CONMED during the third quarter valued at about $28,000. Quarry LP increased its stake in CONMED by 244.8% during the third quarter. Quarry LP now owns 869 shares of the company’s stock valued at $41,000 after acquiring an additional 617 shares during the period. Sherbrooke Park Advisers LLC bought a new position in CONMED during the third quarter valued at about $211,000. iSAM Funds UK Ltd acquired a new position in CONMED in the 2nd quarter valued at approximately $215,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of CONMED by 107.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,248 shares of the company’s stock worth $221,000 after acquiring an additional 2,205 shares during the period.

About CONMED

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.